CY1114488T1 - Διεργασιες και ενδιαμεσα για την παρασκευη ενος μακροκυκλικου αναστολεα πρωτεασης του hcv - Google Patents

Διεργασιες και ενδιαμεσα για την παρασκευη ενος μακροκυκλικου αναστολεα πρωτεασης του hcv

Info

Publication number
CY1114488T1
CY1114488T1 CY20131100890T CY131100890T CY1114488T1 CY 1114488 T1 CY1114488 T1 CY 1114488T1 CY 20131100890 T CY20131100890 T CY 20131100890T CY 131100890 T CY131100890 T CY 131100890T CY 1114488 T1 CY1114488 T1 CY 1114488T1
Authority
CY
Cyprus
Prior art keywords
preparation
intermediates
microcyclic
hcv
procedures
Prior art date
Application number
CY20131100890T
Other languages
Greek (el)
English (en)
Inventor
Andras Horvath
Dominic John Ormerod
Dominique Paul Michel Depré
Véronique Cerpentier
Original Assignee
Janssen Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals, Inc. filed Critical Janssen Pharmaceuticals, Inc.
Publication of CY1114488T1 publication Critical patent/CY1114488T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/475—Preparation of carboxylic acid esters by splitting of carbon-to-carbon bonds and redistribution, e.g. disproportionation or migration of groups between different molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Furan Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CY20131100890T 2008-12-23 2013-10-10 Διεργασιες και ενδιαμεσα για την παρασκευη ενος μακροκυκλικου αναστολεα πρωτεασης του hcv CY1114488T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08172691 2008-12-23
EP09801447.5A EP2382198B1 (en) 2008-12-23 2009-12-22 Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv

Publications (1)

Publication Number Publication Date
CY1114488T1 true CY1114488T1 (el) 2016-10-05

Family

ID=40548041

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100890T CY1114488T1 (el) 2008-12-23 2013-10-10 Διεργασιες και ενδιαμεσα για την παρασκευη ενος μακροκυκλικου αναστολεα πρωτεασης του hcv

Country Status (22)

Country Link
US (2) US8927722B2 (enExample)
EP (1) EP2382198B1 (enExample)
JP (1) JP5687631B2 (enExample)
KR (1) KR101734507B1 (enExample)
CN (1) CN102264715B (enExample)
AR (1) AR074863A1 (enExample)
AU (1) AU2009331530B2 (enExample)
BR (1) BRPI0923393B1 (enExample)
CA (1) CA2745565C (enExample)
CY (1) CY1114488T1 (enExample)
DK (1) DK2382198T3 (enExample)
ES (1) ES2429013T3 (enExample)
HR (1) HRP20130906T1 (enExample)
IL (1) IL213246A (enExample)
MX (1) MX2011006764A (enExample)
PL (1) PL2382198T3 (enExample)
PT (1) PT2382198E (enExample)
RU (1) RU2016120007A (enExample)
SI (1) SI2382198T1 (enExample)
SM (1) SMT201300116B (enExample)
TW (1) TWI461424B (enExample)
WO (1) WO2010072742A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2382198T3 (da) 2008-12-23 2013-09-30 Janssen Pharmaceuticals Inc Fremgangsmåder og mellemprodukter til fremstilling af en makrocyklisk inhibitor af hcv-protease
TWI565704B (zh) 2011-09-22 2017-01-11 健生醫藥公司 用於製備hcv巨環蛋白酶抑制劑之方法及中間物
JP6231482B2 (ja) 2011-10-28 2017-11-15 ヤンセン ファーマシューティカルズ,インコーポレーテッド 大環状プロテアーゼ阻害剤tmc435の中間体の改善された製造方法
CN103387509B (zh) * 2012-05-11 2016-06-08 重庆博腾制药科技股份有限公司 一种hcv蛋白酶抑制剂中间体的制备方法
IN2014MN02652A (enExample) 2012-06-08 2015-08-21 Gilead Sciences Inc
AR091279A1 (es) * 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
SI2859009T1 (sl) * 2012-06-08 2017-12-29 Gilead Sciences, Inc. Makrociklični inhibitorji flaviviridae virusov
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
JP6511432B2 (ja) 2013-03-15 2019-05-15 ギリアード サイエンシーズ, インコーポレイテッド C型肝炎ウイルスの大環状二環式阻害剤
CN105308043B (zh) * 2014-05-29 2018-01-30 杭州普晒医药科技有限公司 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
MA41812A (fr) 2015-03-27 2018-01-30 Janssen Pharmaceuticals Inc Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8300536A (nl) 1983-02-14 1984-09-03 Oce Andeno Bv Optisch actief alfa-azido-p-hydroxyfenylazijnzuur en zijn zouten alsmede de bereiding daarvan.
JPS6124539A (ja) 1984-07-11 1986-02-03 Sagami Chem Res Center 光学活性(r)−2,5,12−トリヒドロキシ−1,2,3,4−テトラヒドロナフタセン−6,11−ジオン−2−カルボン酸の取得方法
JP4218040B2 (ja) 1997-12-26 2009-02-04 曽田香料株式会社 有機酸とアミンの複合塩の製造法
JP3844112B2 (ja) 2000-08-23 2006-11-08 高砂香料工業株式会社 3,5,6−トリヒドロキシヘキサン酸アンモニウム塩誘導体、及びその製造方法
ES2336009T3 (es) 2004-01-30 2010-04-07 Medivir Ab Inhibidores de la ns-3 serina proteasa del vhc.
CN101146806A (zh) 2005-01-21 2008-03-19 阿斯泰克斯治疗有限公司 用于抑制cdk和gsk的吡唑衍生物
EP1919904B1 (en) * 2005-07-29 2014-01-08 Janssen R&D Ireland Macrocyclic inhibitors of hepatitis c virus
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
RU2483067C2 (ru) * 2007-02-01 2013-05-27 Тиботек Фармасьютикалз Лтд. Способы и промежуточные продукты для получения макроциклического ингибитора протеазы вируса гепатита с
MX2009008541A (es) * 2007-02-08 2009-08-18 Tibotec Pharm Ltd Fenilcarbamatos macrociclicos que inhiben el virus de hepatitis c.
DK2382198T3 (da) 2008-12-23 2013-09-30 Janssen Pharmaceuticals Inc Fremgangsmåder og mellemprodukter til fremstilling af en makrocyklisk inhibitor af hcv-protease

Also Published As

Publication number Publication date
KR20110099048A (ko) 2011-09-05
MX2011006764A (es) 2011-08-03
CA2745565C (en) 2017-03-07
US20110257403A1 (en) 2011-10-20
EP2382198A1 (en) 2011-11-02
DK2382198T3 (da) 2013-09-30
CN102264715A (zh) 2011-11-30
TW201033205A (en) 2010-09-16
RU2016120007A (ru) 2018-11-13
SI2382198T1 (sl) 2013-11-29
JP2012513381A (ja) 2012-06-14
BRPI0923393B1 (pt) 2018-06-19
IL213246A0 (en) 2011-07-31
US20150080577A1 (en) 2015-03-19
BRPI0923393A2 (pt) 2015-07-28
PL2382198T3 (pl) 2013-11-29
AU2009331530B2 (en) 2015-04-09
AU2009331530A1 (en) 2011-06-23
SMT201300116B (it) 2013-11-08
US8927722B2 (en) 2015-01-06
PT2382198E (pt) 2013-10-01
WO2010072742A1 (en) 2010-07-01
HRP20130906T1 (hr) 2013-10-25
EP2382198B1 (en) 2013-07-10
AR074863A1 (es) 2011-02-16
CA2745565A1 (en) 2010-07-01
CN102264715B (zh) 2015-12-02
KR101734507B1 (ko) 2017-05-11
HK1164839A1 (zh) 2012-09-28
ES2429013T3 (es) 2013-11-12
IL213246A (en) 2017-10-31
JP5687631B2 (ja) 2015-03-18
RU2011130895A (ru) 2013-01-27
TWI461424B (zh) 2014-11-21
US9115077B2 (en) 2015-08-25

Similar Documents

Publication Publication Date Title
CY1125550T1 (el) Ορισμενες τριαζολοπυραζινες, συνθεσεις αυτων και μεθοδοι για τη χρηση αυτων
FIC20220033I1 (fi) Finerenoni sekä sen suolat, solvaatit ja suolojen solvaatit
CY2017024I1 (el) Παραγωγα αζετιδινης και κυκλοβουτανιου ως αναστολεις των jak
CY1121364T1 (el) Νεοι κυτταροστατικοι νουκλεοζιτες 7-δεαζαπουρινης
BRPI0818003A2 (pt) inibidores de csf-1r, composições e métodos de uso
EA201000777A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BRPI0812159A2 (pt) inibidores de csf-1r, composições e métodos de uso
BRPI0920263A2 (pt) composto, uso do composto, composição, e, método
HUE056636T2 (hu) Cisz-1,1,1,4,4,4-hexafluor-2-butén azeotróp-jellegû készítményei
CY1118231T1 (el) Συνθεση λιποσωματος
EA201101620A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
CR11861A (es) Compuestos organicos
CL2009001452S1 (es) Pieza agarre cabezal de cuchillas.
PT2963031T (pt) Pró-fármacos de tetrahidrocanabinol, composições compreendendo pró-fármacos de tetrahidrocanabinol e métodos de utilização dos mesmos
BRPI0908100A2 (pt) produto combinação, uso de um composto, e, método de tratar câncer
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
BRPI0918122A8 (pt) molécula de diabody, diabody, e mólecula dart
CY1112653T1 (el) Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης
CY1122115T1 (el) Παραγωγα ν1-ακυλο-5-φθοροπυριμιδινονης
BRPI0816350A2 (pt) Composições orais, produtos e métodos de uso
SMP200900065B (it) Derivati ciclizzati come inibitori di EG-5.
DK3348624T3 (da) Sammensætninger, der omfatter hfc-1234yf
BRPI0924081A2 (pt) DERIVADOS DE 5- AMINO -2-(1-hIDROXI-ETIL)- TETRAHIDROPIRANO.
CY1115218T1 (el) Αλας οργανικης αμινης 6-φθορο-3-υδροξυ-2-πυραζινοκαρβονιτριλιου και μεθοδος για την παραγωγη αυτου